ClinicalTrials.gg
RecruitingNCT07519187Updated Jun 9, 2026

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

An Early Phase 1 interventional study of CAR 70-BCMA CAR-T in Relapsed or Refractory Plasma Cell Neoplasms, sponsored by The General Hospital of Western Theater Command. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Primary conditionNeoplasms, Plasma CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasms, Plasma Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Neoplasms, Plasma Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The General Hospital of Western Theater Command · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Neoplasms, Plasma Cell with a site in China — 20 open to participants now, 21 under way, 1 of them phase 3. Neoplasms, Plasma Cell · China.

Planned enrollment
14th of 28
20 · median 20
Started
2026
with 5 others
Phase 1
10 of 32
7 open now
Primary completion
2027-04
later than 14 of 20 live
Registered
29th of 32
by date

Among the 32 studies in Neoplasms, Plasma Cell with a site in China, this one is the 14th largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 14 of the 20 other live ones, and was the 29th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

20 of the 32 studies in Neoplasms, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Neoplasms, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

03

Conditions studied

  • Relapsed or Refractory Plasma Cell Neoplasms

Browse trials for

Keywords

  • Relapsed and Refractory Plasma Cell Neoplasms.
  • BCMA
  • CD70
  • CAR-T
04

In context

Neoplasms, Plasma Cell Reclassified

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 527 interventional studies indexed under Neoplasms, Plasma Cell.

Browse Neoplasms, Plasma Cell studies →

Lead sponsor

The General Hospital of Western Theater Command is the lead sponsor of 12 studies on the registry; 10 are open to participants now.

Compared within Neoplasms, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject or their legally authorized representative has provided written and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures
  2. Diagnosis of plasma cell neoplasms, defined as follows:

    • Clonal plasma cells positive for BCMA and/or CD70 expression as determined by flow cytometry or immunohistochemistry
    • Patients with multiple myeloma, plasmacytoma, or plasma cell leukemia who have received at least three , including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR
    • Patients with systemic light chain amyloidosis who have received at least two prior lines of therapy, including an anti-CD38 monoclonal antibody and either a proteasome inhibitor (PI) or an immunomodulatory agent (IMiD), and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR
  3. Aged 18 to 75 years (inclusive), male or female
  4. (ECOG) performance status of 0 to 2
  5. greater than 3 months from the date of informed consent
  6. (HGB) ≥ 60 g/L (transfusion permitted)
  7. Adequate hepatic, renal, cardiac, and pulmonary function meeting the following criteria:

    • Creatinine ≤ 2 × (ULN)
    • (LVEF) ≥ 50%
    • Oxygen saturation > 90%
    • Total ≤ 1.5 × ULN; (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
  8. The subject agrees to use measures from the time of signing the informed consent form until 1 year after CAR-T cell infusion

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac dysfunction with (LVEF) \< 50%
  • History of severe pulmonary function impairment
  • Concurrent progressive
  • Concurrent severe infection that cannot be adequately controlled
  • Concurrent severe disease or congenital immunodeficiency
  • Active hepatitis, defined as virus deoxyribonucleic acid (HBV-DNA) or virus ribonucleic acid (HCV-RNA) above the lower limit of detection
  • (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection
  • History of severe allergic reaction to biological products (including antibiotics)
  • Patients who have undergone hematopoietic stem cell transplantation and still have acute (GVHD) one month after discontinuation of agents
  • Presence of any other serious physical or mental illness, or laboratory abnormality that may increase the risk of study participation, interfere with the interpretation of study results, or render the patient unsuitable for study enrollment in the opinion of the investigator
  • Female patients of who are pregnant or breastfeeding
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    This is a single arm treatment of CAR 70-BCMA CAR-T cell

    CAR 70-BCMA CAR-T Therapy. Investigational product: CAR 70-BCMA CAR-T. Route of administration: Intravenous injection. Lymphodepleting chemotherapy regimen: A combination of fludarabine and cyclophosphamide will be administered prior to the infusion of CAR 70-BCMA CAR-T cells.

    Genetic: CAR 70-BCMA CAR-T

Interventions

  • GeneticCAR 70-BCMA CAR-T

    Each subject will receive a single infusion of BCMA-CD70-CAR-T cells. A classic "3+3" dose escalation design will be employed.

07

What researchers measure

Primary outcomes

  1. To evaluate the safety of CAR70-BCMA dual-target chimeric antigen receptor T-cell therapy in patients with relapsed or refractory plasma cell neoplasms expressing CD70 and/or BCMA based on the incidence of treatment-emergent adverse events (AEs).

    Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: Up to 3 years

  2. To evaluate the safety of CAR70-BCMA CAR-T cells in the treatment of relapsed or refractory plasma cell neoplasms positive for CD70/BCMA based on the determination of the maximum tolerated dose (MTD).

    Incidence of dose-limiting toxicity (DLT)

    Time frame: Up to 28 days after CAR-T treatment

Secondary outcomes

  1. To evaluate the efficacy of CAR70-BCMA CAR-T cells in the treatment of relapsed or refractory plasma cell neoplasms positive for CD70/BCMA based on the objective response rate (ORR).

    Objective response rate (ORR) Description: For multiple myeloma (plasma cell neoplasms, plasma cell leukemia), the efficacy evaluation criteria refer to the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (2024 Revision). ORR includes the proportion of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), and minimal response (MR).

    Time frame: Within 3 months following infusion of CAR70-BCMA CAR-T cells

Other outcomes

  1. To explore the kinetics and clonal evolution of CAR70-BCMA CAR-T cells based on pharmacokinetics (assessing the persistence of CAR-T cells by measuring CAR-T cell counts in peripheral blood).

    After infusion of CAR70-BCMA CAR-T cells, the CAR positivity rate in peripheral blood using flow cytometry and measuring CAR-T expression levels with qPCR.

    Time frame: Up to 12 months after CAR-T treatment

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 35 non-industry phase 1 interventional studies under Neoplasms, Plasma Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 96. This study's planned 11 months is below that.

Counting every sponsor, half of 51 studies reached it within 61 months; a quarter within 27 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07519187
Lead sponsor
The General Hospital of Western Theater Command
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 23, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Jun 9, 2026

Study contacts

Hai Yi
Contact
yihaimail@163.com
13699418229

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion